Thinking of joining a study?

Register your interest

NCT06515860 | RECRUITING | Neurofibromatosis Type 1


Neurofibromatosis Type 1 Tumor Early Detection Study
Sponsor:

David Miller

Information provided by (Responsible Party):

David Miller

Brief Summary:

The goal of this observational study is to determine if a liquid biopsy (i.e. blood test) is an effective clinical tool for monitoring the development of malignant peripheral nerve sheath tumor (MPNST) among adults (18 years and older) with Neurofibromatosis Type 1 (NF1), compared to the current standard of care. The main questions it aims to answer are: How effective is liquid biopsy compared to the current standard of care (clinical surveillance and imaging) for early detection of MPNST development among people with NF1? Can liquid biopsy offer a cost-effective method for early detection of MPNST in people with NF1? Also, can liquid biopsy provide earlier detection that potentially leads to better outcomes? Also, can offering liquid biopsy improve access to care for people experiencing barriers to access (such as minority populations or people in rural areas)? At baseline, participants will be asked to: * Complete surveys to provide their demographic and NF1-related health information. * Report whether or not they are experiencing MPNST-related symptoms. * Provide blood samples (15 mL blood total between three tubes, which is approximately one tablespoon). Every six months during the five-year follow-up period, participants will be asked to: * Complete additional surveys to report whether or not they are experiencing MPNST-related symptoms and/or if they have been diagnosed with a new MPNST. * Provide an additional blood sample (10 mL blood total in one tube). If diagnosed with an MPNST by their healthcare provider during the follow-up period, participants will be asked to: * Complete an additional survey regarding their diagnosis and symptoms. * Provide an additional blood sample (10 mL blood in one tube). * In parallel, the study team will request a sample of tumor tissue from the care provider, if available.

Condition or disease

Neurofibromatosis Type 1

Neurofibromatosis 1

Plexiform Neurofibroma

Plexiform Neurofibromas

Malignant Peripheral Nerve Sheath Tumor

Malignant Peripheral Nerve Sheath Tumors

Atypical Neurofibroma

Intervention/treatment

Liquid biopsy for MPNST development

Study Type : OBSERVATIONAL
Estimated Enrollment : 1000 participants
Official Title : Observational Trial of Liquid Biopsy for Malignant Peripheral Nerve Sheath Tumor (MPNST) Among Participants With Neurofibromatosis Type 1
Actual Study Start Date : 2024-08-07
Estimated Primary Completion Date : 2030-07
Estimated Study Completion Date : 2030-07

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * 18 years and older (adults only)
  • * Neurofibromatosis Type 1 (NF1) diagnosis (2021 Revised Diagnostic Criteria, PMID: 34012067)
  • * History of plexiform neurofibroma (PN)
  • * Able to read and understand English or Spanish
  • * Live in the USA
Exclusion Criteria
  • * Are children (younger than 18 years old)
  • * Do not have NF1
  • * Have no evidence of PN
  • * Are not able to read and understand English or Spanish

Neurofibromatosis Type 1 Tumor Early Detection Study

Location Details

NCT06515860


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


RECRUITING

United States, Massachusetts

Boston Children's Hospital

Boston, Massachusetts, United States, 02115

Loading...